These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 21685905)

  • 1. A pipeline that integrates the discovery and verification of plasma protein biomarkers reveals candidate markers for cardiovascular disease.
    Addona TA; Shi X; Keshishian H; Mani DR; Burgess M; Gillette MA; Clauser KR; Shen D; Lewis GD; Farrell LA; Fifer MA; Sabatine MS; Gerszten RE; Carr SA
    Nat Biotechnol; 2011 Jun; 29(7):635-43. PubMed ID: 21685905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Streamlining biomarker discovery.
    Latterich M; Schnitzer JE
    Nat Biotechnol; 2011 Jul; 29(7):600-2. PubMed ID: 21747385
    [No Abstract]   [Full Text] [Related]  

  • 3. A targeted proteomics-based pipeline for verification of biomarkers in plasma.
    Whiteaker JR; Lin C; Kennedy J; Hou L; Trute M; Sokal I; Yan P; Schoenherr RM; Zhao L; Voytovich UJ; Kelly-Spratt KS; Krasnoselsky A; Gafken PR; Hogan JM; Jones LA; Wang P; Amon L; Chodosh LA; Nelson PS; McIntosh MW; Kemp CJ; Paulovich AG
    Nat Biotechnol; 2011 Jun; 29(7):625-34. PubMed ID: 21685906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aptamer-Based Proteomic Profiling Reveals Novel Candidate Biomarkers and Pathways in Cardiovascular Disease.
    Ngo D; Sinha S; Shen D; Kuhn EW; Keyes MJ; Shi X; Benson MD; O'Sullivan JF; Keshishian H; Farrell LA; Fifer MA; Vasan RS; Sabatine MS; Larson MG; Carr SA; Wang TJ; Gerszten RE
    Circulation; 2016 Jul; 134(4):270-85. PubMed ID: 27444932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma.
    Addona TA; Abbatiello SE; Schilling B; Skates SJ; Mani DR; Bunk DM; Spiegelman CH; Zimmerman LJ; Ham AJ; Keshishian H; Hall SC; Allen S; Blackman RK; Borchers CH; Buck C; Cardasis HL; Cusack MP; Dodder NG; Gibson BW; Held JM; Hiltke T; Jackson A; Johansen EB; Kinsinger CR; Li J; Mesri M; Neubert TA; Niles RK; Pulsipher TC; Ransohoff D; Rodriguez H; Rudnick PA; Smith D; Tabb DL; Tegeler TJ; Variyath AM; Vega-Montoto LJ; Wahlander A; Waldemarson S; Wang M; Whiteaker JR; Zhao L; Anderson NL; Fisher SJ; Liebler DC; Paulovich AG; Regnier FE; Tempst P; Carr SA
    Nat Biotechnol; 2009 Jul; 27(7):633-41. PubMed ID: 19561596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of Large-Scale Aptamer-Based Proteomic Profiling to Planned Myocardial Infarctions.
    Jacob J; Ngo D; Finkel N; Pitts R; Gleim S; Benson MD; Keyes MJ; Farrell LA; Morgan T; Jennings LL; Gerszten RE
    Circulation; 2018 Mar; 137(12):1270-1277. PubMed ID: 29222138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein biomarker discovery and validation: the long and uncertain path to clinical utility.
    Rifai N; Gillette MA; Carr SA
    Nat Biotechnol; 2006 Aug; 24(8):971-83. PubMed ID: 16900146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new data mining approach for profiling and categorizing kinetic patterns of metabolic biomarkers after myocardial injury.
    Baumgartner C; Lewis GD; Netzer M; Pfeifer B; Gerszten RE
    Bioinformatics; 2010 Jul; 26(14):1745-51. PubMed ID: 20483816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging Affinity-Based Proteomic Technologies for Large-Scale Plasma Profiling in Cardiovascular Disease.
    Smith JG; Gerszten RE
    Circulation; 2017 Apr; 135(17):1651-1664. PubMed ID: 28438806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantification of cardiovascular biomarkers in patient plasma by targeted mass spectrometry and stable isotope dilution.
    Keshishian H; Addona T; Burgess M; Mani DR; Shi X; Kuhn E; Sabatine MS; Gerszten RE; Carr SA
    Mol Cell Proteomics; 2009 Oct; 8(10):2339-49. PubMed ID: 19596694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolite profiling of blood from individuals undergoing planned myocardial infarction reveals early markers of myocardial injury.
    Lewis GD; Wei R; Liu E; Yang E; Shi X; Martinovic M; Farrell L; Asnani A; Cyrille M; Ramanathan A; Shaham O; Berriz G; Lowry PA; Palacios IF; Taşan M; Roth FP; Min J; Baumgartner C; Keshishian H; Addona T; Mootha VK; Rosenzweig A; Carr SA; Fifer MA; Sabatine MS; Gerszten RE
    J Clin Invest; 2008 Oct; 118(10):3503-12. PubMed ID: 18769631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MRM for the verification of cancer biomarker proteins: recent applications to human plasma and serum.
    Chambers AG; Percy AJ; Simon R; Borchers CH
    Expert Rev Proteomics; 2014 Apr; 11(2):137-48. PubMed ID: 24476379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiplexed, Quantitative Workflow for Sensitive Biomarker Discovery in Plasma Yields Novel Candidates for Early Myocardial Injury.
    Keshishian H; Burgess MW; Gillette MA; Mertins P; Clauser KR; Mani DR; Kuhn EW; Farrell LA; Gerszten RE; Carr SA
    Mol Cell Proteomics; 2015 Sep; 14(9):2375-93. PubMed ID: 25724909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myocardial Injury Is Distinguished from Stable Angina by a Set of Candidate Plasma Biomarkers Identified Using iTRAQ/MRM-Based Approach.
    Cheow ESH; Cheng WC; Yap T; Dutta B; Lee CN; Kleijn DPV; Sorokin V; Sze SK
    J Proteome Res; 2018 Jan; 17(1):499-515. PubMed ID: 29068691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Qualification and Verification of Protein Biomarker Candidates.
    Zhao Y; Brasier AR
    Adv Exp Med Biol; 2016; 919():493-514. PubMed ID: 27975232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative proteomic analysis of human plasma using tandem mass tags to identify novel biomarkers for herpes zoster.
    Wang T; Shen H; Deng H; Pan H; He Q; Ni H; Tao J; Liu S; Xu L; Yao M
    J Proteomics; 2020 Aug; 225():103879. PubMed ID: 32585426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity.
    Amacher DE
    Toxicol Appl Pharmacol; 2010 May; 245(1):134-42. PubMed ID: 20219512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein biomarkers of new-onset cardiovascular disease: prospective study from the systems approach to biomarker research in cardiovascular disease initiative.
    Yin X; Subramanian S; Hwang SJ; O'Donnell CJ; Fox CS; Courchesne P; Muntendam P; Gordon N; Adourian A; Juhasz P; Larson MG; Levy D
    Arterioscler Thromb Vasc Biol; 2014 Apr; 34(4):939-45. PubMed ID: 24526693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The bottleneck in the cancer biomarker pipeline and protein quantification through mass spectrometry-based approaches: current strategies for candidate verification.
    Makawita S; Diamandis EP
    Clin Chem; 2010 Feb; 56(2):212-22. PubMed ID: 20007861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteomic Discovery and Validation of the Confounding Effect of Heparin Administration on the Analysis of Candidate Cardiovascular Biomarkers.
    Beck HC; Jensen LO; Gils C; Ilondo AMM; Frydland M; Hassager C; Møller-Helgestad OK; Møller JE; Rasmussen LM
    Clin Chem; 2018 Oct; 64(10):1474-1484. PubMed ID: 30115630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.